(1) Background: The prevalence of cancer patients relying on cardiac implantable electronic device (CIED) is steadily rising. The aim of this study was to evaluate RT-related malfunctions of CIEDs. (2) Methods: We retrospectively analyze sixteen patients with esophageal cancer who were treated with radiotherapy between 2012 and 2022 at the University Hospital Heidelberg. All patients underwent systemic evaluation including pre-therapeutic cardiological examinations of the CIED functionality and after every single irradiation. (3) Results: Sixteen patients, predominantly male (14) with a mean age of 77 (range: 56–85) years were enrolled. All patients received 28 fractions of radiotherapy with a cumulative total dose 58.8 Gy. The mean maximum dose at the CIEDs was 1.8 Gy. Following radiotherapy and during the one-year post-radiation follow-up period, there were no registered events associated with the treatment in this evaluation. (4) Conclusion: The study did not observe any severe CIED malfunctions following each radiation fraction or after completion of RT. Strict selection of photon energy and alignment with manufacturer-recommended dose limits appear to be important. Our study showed no major differences in the measured values of the pacing threshold, sensing threshold and lead impedance after RT.
(1) 背景：依赖心脏植入式电子设备（CIED）的癌症患者患病率持续上升。本研究旨在评估放射治疗（RT）相关的CIED功能障碍。(2) 方法：我们回顾性分析了2012年至2022年间在海德堡大学医院接受放射治疗的16例食管癌患者。所有患者均接受系统性评估，包括治疗前CIED功能的心脏学检查及每次单次放疗后的检查。(3) 结果：共纳入16例患者，以男性为主（14例），平均年龄77岁（范围：56-85岁）。所有患者均接受28次放疗，累积总剂量为58.8 Gy。CIED处的平均最大剂量为1.8 Gy。在放疗期间及放疗后一年的随访期内，本次评估未记录到与治疗相关的不良事件。(4) 结论：本研究未观察到每次放疗分次或完成放疗后出现严重的CIED功能障碍。严格选择光子能量并遵循制造商推荐的剂量限制至关重要。我们的研究显示，放疗后起搏阈值、感知阈值和导线阻抗的测量值均未出现显著差异。
肿瘤(癌症)患者之家